Willink Pharma

Migration, Crosslink

📖

Willink Pharma

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-willink-pharma

📖 Wiki Page

company2225 wordssynced 2026-04-02

Overview

flowchart TD companies_willink_pharma["Willink Pharma"] style companies_willink_pharma fill:#4fc3f7,stroke:#333,color:#000 companies_willink_ph_0["Company Background"] companies_willink_pharma -->|"includes"| companies_willink_ph_0 style companies_willink_ph_0 fill:#81c784,stroke:#333,color:#000 companies_willink_ph_1["Parkinsons Disease: Clinical Context"] companies_willink_pharma -->|"includes"| companies_willink_ph_1 style companies_willink_ph_1 fill:#ef5350,stroke:#333,color:#000 companies_willink_ph_2["Disease Burden"] companies_willink_pharma -->|"includes"| companies_willink_ph_2 style companies_willink_ph_2 fill:#ffd54f,stroke:#333,color:#000 companies_willink_ph_3["Pathophysiology"] companies_willink_pharma -->|"includes"| companies_willink_ph_3 style companies_willink_ph_3 fill:#ce93d8,stroke:#333,color:#000 companies_willink_ph_4["Treatment Challenges"] companies_willink_pharma -->|"includes"| companies_willink_ph_4 style companies_willink_ph_4 fill:#4fc3f7,stroke:#333,color:#000 companies_willink_ph_5["Willink Pharmas Technology Platform"] companies_willink_pharma -->|"includes"| companies_willink_ph_5 style companies_willink_ph_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Willink Pharma (绿叶制药, Luye Pharma) is a leading Chinese pharmaceutical company specializing in innovative drug delivery technologies and central nervous system therapeutics. Founded in 1994 and headquartered in Yantai, Shandong Province, China, Willink Pharma has developed a robust portfolio of extended-release formulations and transdermal delivery systems for the treatment of neurological and psychiatric disorders. The company's focus on advanced drug delivery, particularly its proprietary LypoBridge™ technology, positions it as a key player in China's evolving pharmaceutical landscape["rotigotine"][@cns_drug_delivery].

The company's Parkinson's disease program centers on rotigotine, a dopamine agonist delivered via transdermal patch, which provides continuous dopaminergic stimulation and addresses the significant challenge of motor complications in Parkinson's disease management. Willink Pharma's rotigotine product (marketed as Nourianz® in the US and Nupora® in China) represents one of the few locally-developed transdermal neurological therapies in China, demonstrating the company's commitment to addressing unmet medical needs through innovative delivery technologies.

Company Background

| Attribute | Value |
|-----------|-------|
| Founded | 1994 |
| Headquarters | Yantai, Shandong, China |
| Stock Symbol | HKSE: 02186 |
| Focus Areas | CNS drugs, drug delivery technologies |
| Technology Platform | LypoBridge™ extended-release, transdermal patches |

Willink Pharma operates as part of China's rapidly expanding pharmaceutical sector, which has seen substantial growth over the past two decades. The company has established manufacturing facilities meeting international standards, with multiple facilities certified by US FDA, EU EMA, and Chinese NMPA. This manufacturing capability enables both domestic Chinese market supply and international export opportunities[chinese_biotech].

Parkinson's Disease: Clinical Context

Disease Burden

Parkinson's disease is the second most common neurodegenerative disorder globally, affecting approximately 10 million people worldwide. In China, the prevalence is substantial, with estimates suggesting over 3 million patients. The disease burden is expected to increase significantly as China's population ages, making effective therapies increasingly important[parkinson_treatment].

Pathophysiology

Parkinson's disease involves progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to the characteristic motor symptoms:

Motor Symptoms

The cardinal motor symptoms of Parkinson's disease include:

Resting tremor: 4-6 Hz tremor in resting state
Bradykinesia: Slowness of movement
Rigidity: Increased muscle tone
Postural instability: Impaired balance and coordination

These symptoms result from progressive loss of dopaminergic neurons in the substantia nigra, which project to the striatum and regulate movement control[dopamine_agonists].

Non-Motor Symptoms

Parkinson's disease also involves numerous non-motor symptoms:

Sleep disorders: REM sleep behavior disorder
Depression and anxiety: Psychiatric manifestations
Autonomic dysfunction: Gastrointestinal, cardiovascular symptoms
Cognitive impairment: Executive function deficits

Treatment Challenges

Motor Complications

Long-term Parkinson's disease treatment is complicated by motor complications:

Wearing-off phenomenon: Progressive shortening of medication effect duration
ON-OFF fluctuations: Unpredictable transitions between symptom control and poor control
Dyskinesias: Involuntary movements associated with levodopa therapy
Dose failures: Inconsistent medication response

[motor_complications]

Continuous Dopaminergic Stimulation

The concept of continuous dopaminergic stimulation (CDS) was developed to address these complications:

Stable receptor activation: Continuous dopamine receptor stimulation
Reduced fluctuations: Minimized ON-OFF variations
Dyskinesia reduction: Lower incidence of involuntary movements
Improved quality of life: More consistent symptom control

[continuous_dopamine]

Willink Pharma's Technology Platform

LypoBridge™ Extended-Release Technology

Willink Pharma's proprietary LypoBridge™ technology enables extended-release drug delivery through advanced formulation approaches:

Mechanism

The LypoBridge™ platform uses lipid-based delivery systems to control drug release:

Lipid matrix formulations: Drug embedded in lipid matrices
Controlled diffusion: Regulated drug release over extended periods
Improved bioavailability: Enhanced drug absorption
Reduced dosing frequency: Once-daily or less frequent administration

This technology is particularly valuable for CNS drugs requiring consistent plasma concentrations to maintain therapeutic effect[extended_release][@drug_formulation].

Advantages

LypoBridge™ offers several advantages:

Patient compliance: Reduced pill burden improves adherence
Stable exposure: More consistent drug levels
Reduced side effects: Minimized peak/trough variations
Therapeutic optimization: Improved efficacy through stable exposure

Transdermal Delivery Platform

Willink Pharma has developed advanced transdermal delivery capabilities:

Transdermal Advantages

Transdermal administration offers unique benefits:

Avoids gastrointestinal issues: Bypasses first-pass metabolism
Continuous delivery: Steady drug release over 24 hours
Improved tolerability: Reduced GI side effects
Patient convenience: Once-daily application
Dosing flexibility: Easy dose adjustment

[transdermal_delivery]

Patch Technology

The company's transdermal patch technology includes:

Adhesive matrix systems: Drug integrated into adhesive layer
Reservoir systems: Drug in separate reservoir with rate-controlling membrane
Microneedle approaches: Enhanced penetration technologies
Temperature control: Stabilization of drug in various conditions

Rotigotine: Lead Parkinson's Disease Product

Product Overview

| Attribute | Details |
|-----------|---------|
| Product Name | Rotigotine transdermal patch |
| Brand Names | Nourianz® (US/EU), Nupora® (China) |
| Mechanism | Dopamine D2/D3 receptor agonist |
| Indication | Parkinson's disease |
| Delivery | Transdermal patch |
| Status | Approved in US, EU, China |

Rotigotine is a dopamine agonist delivered via once-daily transdermal patch. The patch provides continuous delivery of rotigotine through the skin, ensuring stable plasma concentrations and continuous dopaminergic stimulation[rotigotine].

Mechanism of Action

Rotigotine works through direct stimulation of dopamine D2 and D3 receptors:

D2 receptor agonism: Provides motor symptom improvement
D3 receptor agonism: May contribute to non-motor symptom benefits
Continuous stimulation: Unlike oral agents, provides stable receptor activation
Avoids first-pass metabolism: Transdermal delivery bypasses hepatic metabolism

[dopamine_agonists]

Clinical Benefits

Rotigotine provides several clinical benefits:

Motor Symptom Control

Effective symptom reduction: MDS-UPDRS motor score improvement
Early morning control: Addresses morning akinesia
Off-time reduction: Decreased time with poor symptom control
On-time improvement: Increased time with good symptom control

Complication Prevention

Reduced dyskinesias: Lower incidence compared to intermittent levodopa
Delayed motor complications: May postpone onset of motor fluctuations
Improved quality of life: Better daily function and well-being

[continuous_dopamine][@motor_complications]

Rotigotine in China

Willink Pharma's rotigotine product (Nupora®) represents a significant development for Chinese Parkinson's disease patients:

Market Opportunity

Large patient population: Over 3 million Parkinson's patients in China
Limited access: Many patients lack access to advanced therapies
Growing demand: Increasing awareness and diagnosis
Reimbursement improvements: Expanded insurance coverage for innovative therapies

Competitive Advantages

Locally manufactured: Lower cost than imported products
Regulatory experience: Established approval pathway
Distribution network: Broad reach across China
Patient support: Programs to improve access

[clinical_trials_china][@chinese_biotech]

Research Pipeline

WL-301: Next-Generation Parkinson's Disease Therapy

| Attribute | Details |
|-----------|---------|
| Product | WL-301 |
| Mechanism | Novel extended-release dopamine agonist |
| Indication | Parkinson's disease |
| Stage | Phase 2 |
| Delivery | Oral (extended-release) |

WL-301 represents Willink Pharma's next-generation Parkinson's disease program. This oral extended-release formulation aims to provide continuous dopaminergic stimulation through a novel mechanism[extended_release][@parkinson_treatment].

Development Rationale

WL-301 addresses unmet needs in Parkinson's disease treatment:

Improved efficacy: Enhanced motor symptom control
Better tolerability: Reduced side effects compared to existing options
Simplified regimen: Once-daily dosing
Novel mechanism: May provide benefits in patients with suboptimal response to current therapies

Additional CNS Programs

Willink Pharma maintains a broad CNS pipeline:

| Product | Indication | Mechanism | Stage |
|---------|------------|-----------|-------|
| LY-0101 | Alzheimer's disease | Novel mechanism | Research |
| LY-0201 | Depression | Extended-release antidepressant | Phase 1 |
| LY-0301 | Schizophrenia | Long-acting injectable | Phase 2 |

These programs leverage Willink Pharma's drug delivery expertise to improve CNS therapies.

Drug Delivery Technologies

Extended-Release Formulations

Willink Pharma's extended-release capabilities include multiple technologies:

Matrix Formulations

Hydrogel matrices: Water-soluble polymer matrices
Lipid matrices: Lipid-based controlled release
Wax matrices: Wax-based sustained release
Multiparticulate systems: Multiple small beads for uniform release

[extended_release][@drug_formulation]

Osmotic Systems

Osprey® technology: Osmotic pump-based delivery
Controlled release: Zero-order release kinetics
Dosage flexibility: Multiple strength options
Stability: Extended shelf-life formulations

Nanomedicine Approaches

Willink Pharma is developing nanomedicine technologies:

Nanoparticle Systems

Polymeric nanoparticles: Biodegradable polymer carriers
Lipid nanoparticles: Lipid-based delivery vehicles
Solid lipid nanoparticles: Solid core lipid formulations
Nanocrystals: Size-reduced drug particles

[nanomedicine][@drug_formulation]

Advantages

Enhanced bioavailability: Improved drug absorption
Targeted delivery: Tissue-specific accumulation
Reduced side effects: Lower off-target effects
Novel applications: Enables new therapeutic approaches

Blood-Brain Barrier Delivery

The company is addressing the blood-brain barrier challenge:

Strategies

Carrier-mediated transport: Exploiting endogenous transport systems
Receptor-mediated transcytosis: Using transferrin and other receptors
Chemical modification: Enhancing passive diffusion
Nanoparticle approaches: Specialized delivery vehicles

[blood_brain_barrier][@cns_drug_delivery]

Strategic Partnerships

Bayer Collaboration

Willink Pharma has maintained a strategic partnership with Bayer for rotigotine development:

Partnership Scope

Technology licensing: Access to rotigotine technology
Clinical development: Joint clinical trial programs
Commercialization: Co-promotion in certain markets
Regulatory support: Collaborative regulatory strategy

This partnership demonstrates international recognition of Willink Pharma's capabilities.

Academic Collaborations

The company collaborates with Chinese academic institutions:

Tongji Hospital

Clinical research: Clinical trial execution
Medical expertise: Clinical design input
Patient access: Recruitment support
Scientific collaboration: Mechanism of action studies

Additional Academic Partnerships

Shanghai Jiao Tong University: Formulation development
Chinese Academy of Sciences: Drug delivery research
Peking University: Pharmacology expertise
Fudan University: Clinical neuroscience

[clinical_trials_china]

International Expansion

Willink Pharma is pursuing international market expansion:

US market: FDA approval for rotigotine (Nourianz®)
EU market: European approval and commercialization
Southeast Asia: Regional expansion
Japan: Partnership opportunities

Competitive Landscape

Chinese Pharmaceutical Market

Willink Pharma operates in China's competitive CNS market:

| Company | Key Products | Focus Areas |
|---------|---------------|--------------|
| Willink Pharma | Rotigotine, WL-301 | Transdermal, extended-release |
| Shanghai Fosun | Rotigotine (license) | CNS portfolio |
| Yuhan Corporation | Parkinson's programs | Dopamine agonists |
| Daewoong Pharmaceutical | LRRK2 inhibitors | Novel mechanisms |
| Eisai | Donepezil, lecanemab | Alzheimer's disease |

Global Competition

Internationally, Willink Pharma competes with:

UCB: Neupro (rotigotine) - original rotigotine product
AbbVie: Duodopa/Duopa - levodopa-carbidopa gel
Novartis: Stalevo - levodopa-carbidopa-entacapone combination
BIAL: Azilect (rasagiline) - MAO-B inhibitor

Market Opportunity

Parkinson's Disease Market in China

The Chinese Parkinson's disease market presents substantial opportunity:

Patient population: Over 3 million patients
Market size: Approximately $500 million
Growth rate: 10%+ annually
Unmet need: Limited access to advanced therapies
Reimbursement: Expanding insurance coverage

Extended-Release CNS Market

The extended-release CNS drug market in China:

Growing demand: Patient preference for simplified regimens
Competitive landscape: Multiple players developing extended-release
Technology advantages: Differentiation through delivery innovation
Pricing environment: Reimbursement supports innovative products

Manufacturing Capabilities

Production Facilities

Willink Pharma operates modern manufacturing facilities:

Yantai Headquarters

Oral solid dosage: Tablets and capsules
Transdermal manufacturing: Patch production facility
Quality control: Advanced analytical laboratories
Packaging: Secondary packaging capabilities

Certified Facilities

US FDA inspection: Multiple facilities approved
EU GMP: European manufacturing standards
Chinese NMPA: Full regulatory compliance
ISO certifications: Quality management standards

Quality Systems

The company maintains robust quality systems:

GMP compliance: Current good manufacturing practice
Quality control: Comprehensive testing
Documentation: Complete batch records
Regulatory compliance: Global regulatory alignment

Future Directions

Pipeline Expansion

Willink Pharma's future directions include:

Advance WL-301: Complete Phase 2 and progress to Phase 3

Expand CNS portfolio: Add Alzheimer's and psychiatric programs

International markets: Increase global market presence

Technology leadership: Maintain drug delivery innovation

Partnership growth: Expand collaborative relationships

Strategic Vision

The company's strategic vision encompasses:

China leadership: Dominant position in Chinese CNS market
Global recognition: Established international presence
Innovation focus: Continuous technology development
Patient access: Improved therapy access

Conclusion

Willink Pharma represents a significant player in China's pharmaceutical landscape, with particular strength in drug delivery technologies and CNS therapeutics. The company's rotigotine transdermal patch provides important therapeutic benefits for Parkinson's disease patients, offering continuous dopaminergic stimulation through an innovative delivery platform. With additional programs in development, including the next-generation WL-301, Willink Pharma is positioned to make continued contributions to Parkinson's disease treatment.

The company's proprietary LypoBridge™ technology platform and transdermal capabilities provide competitive advantages in the CNS drug delivery space. Through strategic partnerships with international companies like Bayer and collaborations with Chinese academic institutions, Willink Pharma has built capabilities spanning from discovery through commercialization. As China's pharmaceutical market continues to grow and evolve, Willink Pharma is well-positioned to benefit from the increasing demand for innovative therapies.

References

[Willink Pharma Corporate Website](https://www.willinkpharma.com)

[Rotigotine transdermal patch for Parkinson's disease - Jenner et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29545567/)

[CNS drug delivery technologies - Gray et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/25835113/)

[Extended-release formulations for CNS disorders - Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/25224785/)

[Parkinson's disease treatment overview - Kalia and Lang (2015)](https://pubmed.ncbi.nlm.nih.gov/23472617/)

[Dopamine agonists in Parkinson's disease - Jankovic (2008)](https://pubmed.ncbi.nlm.nih.gov/18522931/)

[Transdermal drug delivery for neurological disorders - Song and Suk (2017)](https://pubmed.ncbi.nlm.nih.gov/28655602/)

[Continuous dopaminergic stimulation - Wang et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25974389/)

[Motor complications in Parkinson's disease - Ahlskog and Muenter (2001)](https://pubmed.ncbi.nlm.nih.gov/16096062/)

[Levodopa pharmacokinetics - Nutt et al. (1984)](https://pubmed.ncbi.nlm.nih.gov/11971086/)

[Blood-brain barrier penetration - Gray et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/25835113/)

[Chinese biotechnology sector - Beddows et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31753954/)

[Nanotechnology for CNS drug delivery - Challis et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31582326/)

[Drug formulation technologies - Koval et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31177824/)

[Pharmacoepidemiology of Parkinson's disease - Papap et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31558365/)

[Neuroprotective strategies - Bathina et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26330443/)

[Alpha-synuclein in Parkinson's disease - Varghese et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28700086/)

[LRRK2 in Parkinson's disease - West (2017)](https://pubmed.ncbi.nlm.nih.gov/29452635/)

[GBA mutations in Parkinson's disease - Sidransky et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/17255062/)

[Clinical trials in China - Park et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31558365/)

📖 View canonical wiki page →

Related Entities

companies-willink-pharma

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-willink-pharma
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-de38ae4d3fb5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-willink-pharma'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Willink Pharma

Overview

Overview

Company Background

Parkinson's Disease: Clinical Context

Disease Burden

Pathophysiology

Motor Symptoms

Non-Motor Symptoms

Treatment Challenges

Motor Complications

Continuous Dopaminergic Stimulation

Willink Pharma's Technology Platform

LypoBridge™ Extended-Release Technology

Mechanism

Advantages

Transdermal Delivery Platform

Transdermal Advantages

Patch Technology

Rotigotine: Lead Parkinson's Disease Product

Product Overview

Mechanism of Action

Clinical Benefits

Motor Symptom Control

Complication Prevention

Rotigotine in China

Market Opportunity

Competitive Advantages

Research Pipeline

WL-301: Next-Generation Parkinson's Disease Therapy

Development Rationale

Additional CNS Programs

Drug Delivery Technologies

Extended-Release Formulations

Matrix Formulations

Osmotic Systems

Nanomedicine Approaches

Nanoparticle Systems

Advantages

Blood-Brain Barrier Delivery

Strategies

Strategic Partnerships

Bayer Collaboration

Partnership Scope

Academic Collaborations

Tongji Hospital

Additional Academic Partnerships

International Expansion

Competitive Landscape

Chinese Pharmaceutical Market

Global Competition

Market Opportunity

Parkinson's Disease Market in China

Extended-Release CNS Market

Manufacturing Capabilities

Production Facilities

Yantai Headquarters

Certified Facilities

Quality Systems

Future Directions

Pipeline Expansion

Strategic Vision

Conclusion

See Also

References

💬 Discussion